Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John M Davis

Showing results (41-50 of 505) with videos related to

Pageof 51
Sort By:
Frontiers in Immunology|December 2, 2024
Editorial: Basic, clinical, and translational studies of Yao syndrome and other NOD2 related diseasesJohn M Davis, Christine McDonald, Qingping Yao
The American Journal of Psychiatry|November 5, 2013
Increasing placebo response in antipsychotic drug trials: let's stop the vicious circleStefan Leucht, Stephan Heres, John M Davis
Seminars in Arthritis and Rheumatism|November 28, 2015
Indirect comparisons of the efficacy of biological agents in patients with psoriatic arthritis with an inadequate response to traditional disease-modifying anti-rheumatic drugs or to non-steroidal anti-inflammatory drugs: A meta-analysisPatompong Ungprasert, Charat Thongprayoon, John M Davis
Clinical Rheumatology|February 8, 2016
Indirect comparisons of the efficacy of subsequent biological agents in patients with psoriatic arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysisPatompong Ungprasert, Charat Thongprayoon, John M Davis
Plos One|June 22, 2017
Factors associated with successful transition among children with disabilities in eight European countriesJohn Ravenscroft, Kerri Wazny, John M Davis
Psychological Medicine|January 9, 2020
Antipsychotic drugs: from 'major tranquilizers' to Neuroscience-based-NomenclatureSpyridon Siafis, John M Davis, Stefan Leucht
JAMA Psychiatry|November 24, 2021
Limitations in Research on Maintenance Treatment for Individuals With Schizophrenia-ReplyStefan Leucht, Spyridon Siafis, John M Davis
European Archives of Psychiatry and Clinical Neuroscience|September 29, 2021
Should 'typical', first-generation antipsychotics no longer be generally used in the treatment of schizophrenia?Stefan Leucht, Maximilian Huhn, John M Davis
Archives of General Psychiatry|June 11, 2003
A meta-analysis of the efficacy of second-generation antipsychoticsJohn M Davis, Nancy Chen, Ira D Glick
The Journal of Clinical Psychiatry|September 13, 2006
Concomitant medications may not improve outcome of antipsychotic monotherapy for stabilized patients with nonacute schizophreniaIra D Glick, Diana Pham, John M Davis
Pageof 51

Showing results (41-50 of 505) with videos related to

Sort By:
Pageof 51
Frontiers in Immunology|December 2, 2024
Editorial: Basic, clinical, and translational studies of Yao syndrome and other NOD2 related diseasesJohn M Davis, Christine McDonald, Qingping Yao
The American Journal of Psychiatry|November 5, 2013
Increasing placebo response in antipsychotic drug trials: let's stop the vicious circleStefan Leucht, Stephan Heres, John M Davis
Seminars in Arthritis and Rheumatism|November 28, 2015
Indirect comparisons of the efficacy of biological agents in patients with psoriatic arthritis with an inadequate response to traditional disease-modifying anti-rheumatic drugs or to non-steroidal anti-inflammatory drugs: A meta-analysisPatompong Ungprasert, Charat Thongprayoon, John M Davis
Clinical Rheumatology|February 8, 2016
Indirect comparisons of the efficacy of subsequent biological agents in patients with psoriatic arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysisPatompong Ungprasert, Charat Thongprayoon, John M Davis
Plos One|June 22, 2017
Factors associated with successful transition among children with disabilities in eight European countriesJohn Ravenscroft, Kerri Wazny, John M Davis
Psychological Medicine|January 9, 2020
Antipsychotic drugs: from 'major tranquilizers' to Neuroscience-based-NomenclatureSpyridon Siafis, John M Davis, Stefan Leucht
JAMA Psychiatry|November 24, 2021
Limitations in Research on Maintenance Treatment for Individuals With Schizophrenia-ReplyStefan Leucht, Spyridon Siafis, John M Davis
European Archives of Psychiatry and Clinical Neuroscience|September 29, 2021
Should 'typical', first-generation antipsychotics no longer be generally used in the treatment of schizophrenia?Stefan Leucht, Maximilian Huhn, John M Davis
Archives of General Psychiatry|June 11, 2003
A meta-analysis of the efficacy of second-generation antipsychoticsJohn M Davis, Nancy Chen, Ira D Glick
The Journal of Clinical Psychiatry|September 13, 2006
Concomitant medications may not improve outcome of antipsychotic monotherapy for stabilized patients with nonacute schizophreniaIra D Glick, Diana Pham, John M Davis
Pageof 51